Pipeline

ABL001

HomePipelineABL001

  • Pipeline
    ABL001
  • Program Target
    VEGF x DLL4
  • Disease Indication
    Solid Tumor
  • Development Stage
    Clinical Development
    (Phase 1a/1b)
Summary
Better anti-cancer efficacy of ABL001 at in vitro/in vivo studies are confirmed with cancer patients in clinical trial (phase 1a/1b).
ABL001 can be developed as the next generation of anti-angiogenic therapy.

MOA of ABL001

Dual blockade of VEGF & DLL4 overcomes VEGF resistance

MOA of ABL001
MOA of ABL001

POC of ABL001 in Preclinical Study

Better efficacy compared to Avastin or anti-DLL4 monotherapy

POC of ABL001 in Preclinical Study
POC of ABL001 in Preclinical Study

Clinical Response of ABL001

3 Patients showed confirmed partial response (PR) in phase 1a/1b study

Clinical Response of ABL001
좌우스크롤 Clinical Response of ABL001